Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 116Carcinoma, Non-Small-Cell Lung 68Multiple Myeloma 56Prostatic Neoplasms 55Lymphoma 40Neoplasm Metastasis 38Leukemia, Lymphocytic, Chronic, B-Cell 35Melanoma 32Leukemia, Myeloid, Acute 32Neoplasms 31Ovarian Neoplasms 30Lymphoma, Non-Hodgkin 27Lung Neoplasms 26Hematologic Neoplasms 25Triple Negative Breast Neoplasms 24Glioblastoma 22Myelodysplastic Syndromes 20Fallopian Tube Neoplasms 20Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Hodgkin Disease 19Sarcoma 18Carcinoma, Renal Cell 18Squamous Cell Carcinoma of Head and Neck 16Small Cell Lung Carcinoma 16Glioma 16Urinary Bladder Neoplasms 15Colorectal Neoplasms 15Lymphoma, Mantle-Cell 14Leukemia 14Head and Neck Neoplasms 14

Interventions

berzosertib 1Magnetic Resonance Spectroscopy 1Irinotecan 1Endoscopy 1Endoscopic Mucosal Resection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Has results × Clinical Stage III Gastric Cancer AJCC v8 × Clear all
NCT03641313 2026-04-13

Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
17 enrolled 14 charts
Gastrointestinal

Clinical Stage III Gastric Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡